Alnylam Pharmaceuticals Inc.

ALNY | NASDAQ

Price Alert Chart Builder DCF Calculator

$244.32

+$4.76 (+1.99%)

At close: Sep 21, 2026, 4:00 PM ET

$244.35

+$0.03 (+0.01%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $32.06B

Enterprise Value $30.65B

Beta 0.30

Average Volume 1.59M

Shares Outstanding (Diluted) 138.25M

Shares Change YoY 6.61%

Institutional Ownership 97.91%

Exchange NASDAQ

ISIN US02043Q1076

Price Performance

Price Change 1M 3.6%

Price Change 3M -15.2%

Price Change 6M -25.7%

Price Change YTD -39.0%

Price Change 1Y -46.8%

Price Change 3Y 42.4%

Price Change 5Y 30.4%

1M CAGR (ann.) 10.8%

1Y CAGR (ann.) -47.0%

5Y CAGR (ann.) 4.8%

All-Time CAGR 13.5%

Valuation

PE Ratio 41.27

Forward PE 25.58

PEG Ratio 0.01

Forward PEG 0.77

PS Ratio 6.80

Forward PS 4.70

PB Ratio 24.14

P/FCF Ratio 60.26

P/Adj. FCF Ratio 158.76

P/OCF Ratio 51.33

EV/Sales 6.38

EV/EBIT 27.97

EV/EBITDA 26.65

EV/FCF 56.50

Earnings Yield 2.4%

FCF Yield 1.7%

Adj. FCF Yield 0.6%

Financial Health

Net Cash $2.04B

Total Debt $1.27B

Cash & Short-Term Investments $3.31B

Total Assets $5.56B

Current Ratio 3.05

Quick Ratio 2.99

Debt / Equity Ratio 0.94

Debt / EBITDA 1.10

Debt / FCF 2.34

OCF / Debt 0.50

Interest Coverage 3.08

Altman Z-Score 5.17

Piotroski F-Score 6

Margins & Profitability

Gross Profit Margin 79.7%

Operating Profit Margin 20.8%

EBITDA Margin 23.9%

Net Profit Margin 16.8%

FCF Margin 11.3%

Adj. FCF Margin 4.3%

SBC / Revenue 7.0%

SBC Impact (per share) -62.1%

Returns

Return on Assets 14.5%

Return on Equity 93.6%

Return on Invested Capital 24.4%

Return on Capital Employed 24.7%

Return on Tangible Assets 14.5%

Historical Growth (CAGR)

Revenue CAGR 3Y 57.2%

Revenue CAGR 5Y 47.5%

Revenue CAGR 10Y 66.2%

EPS CAGR 3Y 343.2%

EPS CAGR 5Y 123.2%

EPS CAGR 10Y 19.8%

FCF CAGR 3Y 41.5%

FCF CAGR 5Y 369.7%

FCF CAGR 10Y 31.0%

Analyst Forecasts

Analyst Rating Buy

Analyst Count 52

EPS Growth Next 3Y 33.1%

Revenue Growth Next 3Y 24.8%

Earnings Date Oct 28, 2026

EPS Estimate (next Q) $1.77

EPS Growth Est (next Q) -3.8%

Revenue Est (next Q) $1.43B

Revenue Growth Est (next Q) 14.4%

Fair Value Estimates

Graham Number $36.79

Graham Upside -84.9%

Lynch Fair Value $148

Lynch Upside -39.4%

Price Target $347.33

Price Target Upside 42.2%

Cash Flow

Operating Cash Flow $634.49M

Free Cash Flow $542.54M

Adj. Free Cash Flow $205.92M

FCF Per Share $4.07

OCF Per Share $4.76

OCF/S Ratio 13.2%

Income Statement

Revenue $4.8B

Gross Profit $3.83B

Operating Income $999.78M

EBITDA $1.15B

Net Income $807.99M

EPS (Diluted) $5.92

Revenue / Employee $1.92M

Profit / Employee $323.2K

Employees 2,500